Member Info for mulledwine

Highlights · Cash balances at period end of £3.6m (2009: £2.3m) · Completed disposal of landfill gas asset, Bryn Posteg, giving a profit on disposal of up to £600k and realising up to £2.75m in cash · Completed disposal of German wind assets to Allianz Renewable Energy Management GmbH for total cash consideration of up to €39.8m, realising up to £7.6m in cash after repayment of project debt · Retain approximately 27% shareholding in Carnegie Wave Energy. At the 31 December 2010 the market value of the shares was approximately £16.8m · Roger Harper appointed to the Board as a Non-Executive Director, replacing Roger Witcomb

http://www.halifaxmarketwatch.co.uk/rns.cgi?username=&ac=&action=news&rns=1&view=full&story_id=4165510

Erlan Sagadiev, CEO of Frontier Mining, commented: "We are delighted to have completed our merger with Coville and to have eliminated any uncertainty that may have remained regarding the transaction. This will allow our management to focus its entire efforts onto bringing our world class Benkala asset into production later this year as planned."

Frontier Mining Ltd ("Frontier" or the "Company") Frontier Completes Acquisition of Coville Frontier Mining Ltd (AIM: FML), the AIM listed gold and copper exploration and development company focused on Kazakhstan, is pleased to announce that it has received written and final approval from both the Ministry of Industry and Trade of Kazakhstan (the "MIT" or the "Ministry") and the Inter-Ministerial Committee (the "IMC") to complete the acquisition of Coville Intercorp Ltd's ("Coville") 50% interest in the Benkala copper project (the "Acquisition"). With this approval the acquisition of Coville is now complete. Both Frontier and Coville, which have already been operating as a single unit, will now be able to move forward toward successfully completing their integration. Coville's shares, which have been held in escrow pending completion of the acquisition, will now be released and are subject to a 12 month holding period. Coville holds 873,215,000 ordinary shares in Frontier representing 46.9% of the issued share capital of Frontier.

http://www.halifaxmarketwatch.co.uk/rns.cgi?username=&ac=&action=news&rns=1&view=full&story_id=4165499

http://www.halifaxmarketwatch.co.uk/rns.cgi?username=&ac=&action=news&rns=1&view=full&story_id=4165523

"The NWR group is further strengthened by today's announced offer in connection with our previously announced intention to re-incorporate NWR in the UK. We have been premium listed in London since our IPO in 2008 and today's announcement about our proposed re-incorporation is designed, alongside our continuing premium listed status, to pave the way for FTSE Index eligibility and further increase the attractiveness of the Company to a broader universe of the highest quality investors in Europe and globally."

http://www.halifaxmarketwatch.co.uk/rns.cgi?username=&ac=&action=news&rns=1&view=full&story_id=4165688

Thomas A. Nicolette, President and CEO, commented, "We are confident that our six proprietary platform technologies position ABI attractively in the global, rapid test marketplace and set the stage for long-term corporate growth. Moving into 2011, ABI is well-positioned to complete the clinical development of a number of novel rapid diagnostic testing solutions and introduce these products into high value markets, towards the end of the year and beyond."

Post Year-End Developments § BreathScan PRO Alcohol Detection System commercialization milestones reached in USA and EU § US FDA 510(k)-clearance granted for Over-the-Counter Use § CE-Mark affixed for professional use § Breath PulmoHealth "Check" line will be extended to include rapid breath condensate screening tests for Asthma and Chronic Obstructive Pulmonary Disease (COPD) in addition to Lung Cancer § Successful £2.16 million equity raise positions ABI to: § fund clinical trials for a number of ABI's diagnostic products which are in the final stages of development prior to commercialization § fund marketing of existing products, particularly through the commissioning of user studies and field trials by comparing the efficacy of ABI's tests against alternative testing methods § invest in ABI's direct-sales capability § Granted US Patent for the Company's Rapid Blood Cell Separation ("Separator") technology. The technology has been integrated into the Lithium "Check" System and will be the basis for the PIFA POC ("Point-of-Care") assay format that will facilitate bedside testing for numerous antibody- and antigen-specific diagnostic devices, including the Company's Heparin/PF4 test

Operational Summary § 37% increase in PIFA Heparin/PF4 Rapid Assay sales over 2009; this represents a strong acceleration in H2 2010 performance due to an increase in product adoption through the expansion of the Company's international distribution network with the addition of Fisher HealthCare and TCoag Germany in Q3 2011 § Licensed the exclusive sales, marketing, and distribution rights to the Company's BreathScan product line in the UK and Republic of Ireland, to London-based BreathScan International Ltd 20% owned by ABI § Comprehensive protocol completed at major US university confirms PIFA Heparin/PF4 Rapid Assay as a rule-out test for Heparin-Induced Thrombocytopenia (HIT) given its highly favourable negative predictive value § Al Tadawi Medical Equip TR LLCdistribution relationship provides ABI with access to diagnostic markets in the Middle East and India for the Company's Tri-Cholesterol "Check", PIFA Chlamydia and Breath Ketone "Check" rapid screening test § Breath Ketone "Check" received CE-Mark for professional use; technical documentation submitted to the FDA for 510(k) Clearance process § Granted additional US Patent for ABI's MicroParticle Catalyzed Biosensor technology and portable key holder unit

Financial Summary § Revenue increased 72% to $3.1 million (2009: $1.8 million) § Gross Profit Margin increased by 18 basis points to 57.8% (2009: 40.3%) § Adjusted Loss Before Tax substantially reduced by 74% to $1.2m (2009 loss: $4.6 million) § Earnings Before Interest, Depreciation, Taxes & Amortization (EBIDTA) increased by 84% to loss: $649k (2009 loss: $4.1 million) § Basic & diluted loss per share substantially reduced by 75% to $0.01 (2009: $0.04) § Inventory at year end: $686k (2009: $677k) § Company is debt free with current assets in cash and cash equivalents at year end of $423k (2009: $2.6 million), which was subsequently increased by the £2.16 million placing in January 2011

yes and its the one with the figures!

Good performance re revenue and profits - negative is debt is up and cash held is down.

Commenting on the Results, John McLean, Non-Executive Chairman of China Food Company plc, said: "The Group has now fully entered the sales and marketing phase of its development, having established the infrastructure to substantially increase production. With a strong team in place and a clear marketing plan, the Group is already capitalising on the increased capacity that it now has, and is pleased to report a strong start to 2011, with condiment sales up significantly. "We believe that China Food is ideally positioned to take advantage of the continued growth in the domestic economy."

Post-period end · Strengthening of the Board with the appointment of Thomas Coley, who, as Senior Vice-president, ran one of the two major operating divisions of Nestlé S.A · Strong start to 2011 with condiment sales up 20.4% in Q1 against 2010

Highlights · Revenue grew by 19.1% to £35.9 million (2009: £30.1 million) · Profit before tax increased by 33.1% to £3.8 million (2009: £2.8 million) · Net assets were £34.5 million (2009: £30.1 million) · Net debt of £9.3 million (2009: £5.8 million) with cash at the year end of £2.9 million (2009: £3.2 million) · £1.0 million in C Notes issued in June 2010 to complete construction of the factory · New factory fully operational with 89 out of the 131 existing fermentation silos filled under Phase 1 · Installed and commissioned four packing lines with a total combined capacity of 210,000 litres/day · Continued benefit from the robust growth within the Chinese domestic market, with GDP growth of over 8% forecasted for 2011

http://www.halifaxmarketwatch.co.uk/rns.cgi?username=&ac=&action=news&rns=1&view=full&story_id=4165561

One step closer

Mr Li Jinming, Chairman of GRAM said: "The receipt of the SASAC approval is a very positive step forward in securing the necessary Chinese regulatory approvals. GRAM remains committed to working with Caledon to complete the possible acquisition of Caledon as soon as possible and our financing banks remain supportive of the possible acquisition. We continue to actively engage with the regulatory authorities in China."